Skip to main content
Article thumbnail
Location of Repository

Upregulation of α7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides

By Cherie E. Bond, Martina Zimmermann and Susan A. Greenfield
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2002). A non-cholinergic, trophic action of acetylcholinesterase on hippocampal neurons in vitro: molecular mechanisms.
    2. (2004). A novel peptide modulates alpha7 nicotinic receptor responses: implications for a possible trophic-toxic mechanism within the brain.
    3. (2003). A peptide derived from acetylcholinesterase induces neuronal cell death: characterisation of possible mechanisms.
    4. (2004). A peptide derived from the C-terminal region of acetylcholinesterase modulates extracellular concentrations of AChE in the substantia nigra.
    5. (2008). Acetylcholinesterase and apoptosis. A novel perspective for an old enzyme.
    6. (1998). Acetylcholinesterase enhances neurite growth and synapse development through alternative contributions of its hydrolytic capacity, core protein, and variable C termini.
    7. (2008). Acetylcholinesterase in cell adhesion, neurite growth and network formation.
    8. (1984). Acetylcholinesterase may have novel functions in the brain.
    9. (2007). Adaptive changes in acetylcholinesterase gene expression as mediators of recovery from chemical and biological insults.
    10. (2006). Alpha7 nicotinic acetylcholine receptor expression in Alzheimer’s disease: receptor densities in brain regions of the APP(SWE) mouse model and in human peripheral blood lymphocytes.
    11. (2000). Alpha7 receptor-selective agonists and modes of alpha7 receptor activation.
    12. (2004). Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1–42)-induced increase in the level of acetylcholinesterase in primary cortical neurones.
    13. (2008). Alvarez A
    14. (2000). Amyloid peptide Abeta(1–42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors.
    15. (2007). Amyloid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter.
    16. (2006). An acetylcholinesterase-derived peptide inhibits endocytic membrane activity in a human metastatic breast cancer cell line.
    17. (1996). An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype.
    18. (2006). ARP, the cleavable C-terminal peptide of ‘‘readthrough’’ acetylcholinesterase, promotes neuronal development and plasticity.
    19. (2001). beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons.
    20. (2001). Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer’s disease.
    21. (1997). Beta-amyloid induced increase in choline flux across PC12 cell membranes.
    22. (2001). beta-Amyloid(1–42) peptide directly modulates nicotinic receptors in the rat hippocampal slice.
    23. (2004). Bioactivity of a peptide derived from acetylcholinesterase in hippocampal organotypic cultures.
    24. (2003). Bioactivity of a peptide derived from acetylcholinesterase: electrophysiological characterization in guinea-pig hippocampus.
    25. (2004). Bioactivity of a peptide derived from acetylcholinesterase: involvement of an ivermectin-sensitive site on the alpha 7 nicotinic receptor.
    26. (2007). Cell-autonomous inhibition of alpha 7-containing nicotinic acetylcholine receptors prevents death of parasympathetic neurons during development.
    27. (2008). Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology.
    28. (1980). Chemical modification and reactivity of sulfhydryls and disulfides of rat brain nicotinic-like acetylcholine receptors.
    29. (2006). Cholesterol interacts with transmembrane alpha-helices M1, M3, and M4 of the Torpedo nicotinic acetylcholine receptor: photolabeling studies using [3H]Azicholesterol.
    30. (1997). Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons.
    31. (2005). Chronic treatment with amyloid beta(1–42) inhibits non-cholinergic high-affinity choline transport in NG108-15 cells through protein kinase C signaling.
    32. (2000). Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs.
    33. (1989). Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators.
    34. (1997). Differential surface expression and phosphorylation of the N-methyl-D-aspartate receptor subunits NR1 and NR2 in cultured hippocampal neurons.
    35. (2001). Direct evidence for an adhesive function in the noncholinergic role of acetylcholinesterase in neurite outgrowth.
    36. (2004). Elements of the C-terminal t peptide of acetylcholinesterase that determine amphiphilicity, homomeric and heteromeric associations, secretion and degradation.
    37. (2000). Excess ‘‘read-through’’ acetylcholinesterase attenuates but the ‘‘synaptic’’ variant intensifies neurodeterioration correlates.
    38. (1992). Excitotoxic cell death.
    39. (2005). Excitotoxicity and amyotrophic lateral sclerosis.
    40. (2007). Expression and subcellular localization of a novel nuclear acetylcholinesterase protein.
    41. (2000). Expression of cholinergic system molecules during development of the chick nervous system.
    42. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
    43. (2007). Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer’s disease.
    44. (1997). Host cell-specific folding and assembly of the neuronal nicotinic acetylcholine receptor alpha7 subunit.
    45. (1993). Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons.
    46. (2005). Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer’s disease patients.
    47. (2002). Induction of acetylcholinesterase expression during apoptosis in various cell types.
    48. (2008). Interactions of acetylcholinesterase with caveolin-I and subsequently with cytochrome c are required for apoptosome formation.
    49. (2005). Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice.
    50. (2009). MillarNS(2008)RIC-3: anicotinic acetylcholine receptorchaperone.Br JPharm 153: S177–S183. Upregulation of a7 Receptors PLoS ONE | 11
    51. (1993). Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium.
    52. (2006). Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors.
    53. (2007). Morphoregulation by acetylcholinesterase in fibroblasts and astrocytes.
    54. (2007). Multiple cascade effects of oxidative stress on astroglia.
    55. (2007). Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity.
    56. (2003). Natural monomeric form of fetal bovine serum acetylcholinesterase lacks the C-terminal tetramerization domain.
    57. (2005). Nicotine upregulates its own receptors through enhanced intracellular maturation.
    58. (2004). Nicotinic acetylcholine receptors and the regulation of neuronal signalling.
    59. (2001). Nicotinic acetylcholine receptors containing alpha 7 subunits on rat cortical neurons do not undergo long-lasting inactivation even when up-regulated by chronic nicotine exposure.
    60. (2006). Nicotinic modulation of gene expression in SHSY5Y neuroblastoma cells.
    61. (2003). Nicotinic receptors and Alzheimer’s disease.
    62. (2005). Nordberg A
    63. (2006). On functions of cholinesterases during embryonic development.
    64. (2004). Overexpression of acetylcholinesterase inhibited cell proliferation and promoted apoptosis in NRK cells.
    65. (2002). Parkinson’s disease, Alzheimer’s disease and motor neurone disease: identifying a common mechanism.
    66. (1983). Possible role of acetylcholinesterase in regulation of postsynaptic receptor efficacy at a central inhibitory synapse of Aplysia.
    67. (2000). Primer3 on the WWW for general users and for biological programmers.
    68. (2007). Reduction in CHT1-mediated choline uptake in primary neurons from presenilin-1 M146V mutant knock-in mice.
    69. (1996). Regulation of acetylcholinesterase expression during neuronal differentiation.
    70. (1996). Regulation of alpha7 nicotinic acetylcholine receptors in the developing rat somatosensory cortex by thalamocortical afferents.
    71. (2003). Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors.
    72. (2001). Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists.
    73. (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
    74. (1984). Relationship of thyrotropin-releasing hormoneinduced spike and plateau phases in cytosolic free Ca2+ concentrations to hormone secretion.
    75. (2005). Ric-3 promotes functional expression of the nicotinic acetylcholine receptor alpha7 subunit in mammalian cells.
    76. (2007). Role of endogenous nicotinic signaling in guiding neuronal development.
    77. (2002). Selective nicotinic receptor consequences in APP(SWE) transgenic mice.
    78. (1998). Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils.
    79. (1986). Stimulation of neuronal acetylcholine receptors induces rapid gene transcription.
    80. (1995). Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants.
    81. (2006). The C-terminal T peptide of cholinesterases: structure, interactions, and influence on protein folding and secretion.
    82. (2000). The importance of being praline: the interaction of praline-rich motifs in signaling proteins with their cognate domains.
    83. (2003). The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers.
    84. (2002). The origin of the molecular diversity and functional anchoring of cholinesterases.
    85. (1998). The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
    86. (2005). The role of excitotoxicity in neurodegeneration.
    87. (1999). The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface.
    88. (2002). Unconventional ligands and modulators of nicotinic receptors.
    89. (2002). Upregulation of neuronal nicotinic receptor subunits alpha4, beta2, and alpha7 in transgenic mice overexpressing human acetylcholinesterase.
    90. (2001). Voltage-gated channels block nicotinic regulation of CREB phosphorylation and gene expression in neurons.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.